Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus – a phase 4 study in India

Safety and efficacy of fixed-dose combination of dapagliflozin and saxagliptin in patients with type 2 diabetes mellitus – a phase 4 study in India

ObjectiveTo determine the post-marketing safety profile of a once-daily fixed-dose combination (FDC) of dapagliflozin (10 mg) and saxagliptin (5 mg) given orally for 24 weeks or until discontinuation, in Indian patients with type 2 diabetes mellitus (T2DM) who are on stable dose of metformin.DesignP...

Full description

Saved in:
Bibliographic Details
Main Authors: S. K. Wangnoo, Sanjay Kumar Bhadada, Faraz Farishta, Girithara Gopalakrishnan Jayaram Naidu, Indira Pattnaik, K. N. Manohar, K. P. Singh, Sandeep Kumar Gupta, H. S. Bharath, Sujoy Ghosh
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Endocrinology
Subjects:
prospective
single-arm
dapagliflozin
saxagliptin
fixed-dose combination
diabetes mellitus type II
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1528801/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2025.1528801/full

Similar Items